MELISSA KIMBERLIN: Open Payments
NPI 1801293915 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$261 in 15 payments from 8 companies in 2025. Trend: 2023 $33 · 2024 $404 · 2025 $261
Food & beverage: $261
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $55 |
| Lundbeck LLC | 3 | $47 |
| Alkermes, Inc. | 2 | $39 |
| Teva Pharmaceuticals USA, Inc. | 2 | $37 |
| Axsome Therapeutics, Inc. | 2 | $29 |
| IDORSIA PHARMACEUTICALS US INC | 1 | $23 |
| Braeburn Inc. | 1 | $17 |
| Vanda Pharmaceuticals Inc. | 1 | $14 |
Products named: CAPLYTA, REXULTI, UZEDY, Auvelity, Quviviq, ARISTADA, LYBALVI, BRIXADI.
Industry payments across IN — which companies pay providers there.
